MarketInOut Stock Screener Log In | Sign Up
 

RenovoRx Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
RenovoRx Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization58.22 mln
Float43.48 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

73 / 100
Outperforming

Debt / Equity

0.04
Debt-free

Pre-Tax Margin

-622%
Severely loss-making

ROE

-138
Deeply negative

Altman Z-Score

6.35
Very strong

Business Description

RenovoRx is a drug development company focused on improving treatment results for cancer patients through targeted combination therapies. Its primary candidate delivers the chemotherapy drug gemcitabine directly via a specialized catheter system called RenovoCath, currently in Phase III trials for locally advanced pancreatic cancer. Founded in 2009, the company is based in Mountain View, California.

Key Fundamentals

EPS-0.31
ROE-138
RPS0.05
ROIC-1,498
ROA-105
EBITDA, mln-12.28
EV / EBITDA-5.17
EV / EBIT-5.16
Revenue, mln1.98
EV / Revenue32.11

Quote Details

Last 1.29
Change 0.02 (1.57%)
Open 1.25
Volume 284,039
Turnover 366,410
Average Volume 464,061

Financial Ratios

Pre-Tax Profit Margin-622
Leverage Ratio1.28
Current Ratio5.74
Price / Book7.80
Price / Tangible Book7.80
Debt / Equity0.04
Price / Sales33.19

Financial Strength

Altman Z-Score6.35
Piotroski F-Score 3 / 9
Short Ratio0.68
Short % of Float2.17

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 13.16% 96 / 100   
1 Month -23.21% 16 / 100   
2 Months 49.36% 97 / 100   
6 Months 50.6% 96 / 100   
1 Year 14.16% 72 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog